Alnylam Pharmaceuticals (ALNY) vs argenx (ARGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
argenx (ARGX) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 2.5% versus a loss of 50.2%. Over five years, ARGX leads with a +178.7% price change compared with +7.7% for ALNY. argenx is the larger company by market cap ($51.48 billion vs $30.04 billion), about 1.7 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (18.1x vs 23.6x for argenx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | ARGX |
|---|---|---|
| Share price | $224.53 | $818.63 |
| Market cap | $30.04B | $51.48B |
| 1-day change | +0.05% | -11.83% |
| YTD return | -43.54% | -2.65% |
| 1-year return | -50.18% | +2.46% |
| 5-year return | +7.66% | +178.69% |
| P/E ratio (TTM) | 37.86 | 31.20 |
| Forward P/E | 18.07 | 23.58 |
| EPS (TTM) | $5.93 | $26.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | — |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | $1.29B |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $495.55 | $1,072.75 |
| 52-week low | $197.81 | $661.85 |
| Distance from 52-week high | -54.69% | -23.69% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +65.29% | +43.17% |
| Average volume | 1.78M | 283.40K |
| Shares outstanding | 133.81M | 62.89M |
| Employees | 2,500 | 1,863 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARGX has outperformed ALNY by 52.6 percentage points over the past year.
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
ALNY vs ARGX FAQ
Which is bigger, Alnylam Pharmaceuticals or argenx?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $30.04B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or ARGX?
ARGX returned +2.46% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or ARGX?
ARGX has the lower trailing P/E at 31.2, versus 37.9 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and argenx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alnylam Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for argenx.